Northwest Biotherapeutics, Inc.

Northwest Biotherapeutics, Inc. is a biotechnology company that develops personalized immune therapies for cancer in the United States and internationally. Established in 1996 and headquartered in Bethesda, Maryland, the company is focused on its platform technology, called DCVax, which uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer.

The company’s lead product, DCVax-L, has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. This product is designed to target the patient’s specific tumor antigens, and has been shown to provide a significant improvement in overall survival rates compared to the standard of care. In addition, Northwest Biotherapeutics is also developing DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors.

Northwest Biotherapeutics has a strong commitment to its research and development activities, and has invested heavily in its clinical trial processes. The company has a number of ongoing clinical trials in the United States and Europe, and has established collaborations with leading academic institutions and cancer centers. Northwest Biotherapeutics has also formed strategic partnerships with other biotechnology companies to develop and commercialize its products.

The company has been successful in raising funds to support its operations, and in 2018 it completed a $30 million private placement. In addition, Northwest Biotherapeutics has received grant funding from the National Cancer Institute and other government agencies. It has also received funding from private foundations and philanthropic organizations.

Northwest Biotherapeutics is committed to advancing its personalized cancer therapies, and is focused on providing innovative treatments that can improve the lives of patients with cancer.